Intravenous (IV) fosfomycin offers a novel therapeutic option in the treatment of systemic multi-drug resistant (MDR) infections. Unanswered questions remain regarding its efficacy and specific role in our therapeutic arsenal.
Daniel Anderson, PharmD
Advertisement
Articles by Daniel Anderson, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Reductions in Funding, Personnel Will Leave US Less Prepared for Future Infectious Disease Outbreaks
2
Invivyd doses first participants in phase 3 COVID-19 trial of VYD2311
3
ASM Initiative Aims to Advance Phage Therapy for Drug-Resistant Infections
4
Challenges to Adopting New Therapeutics: Familiarity, Diagnostics, and Real-World Use in Persistent Bacteremia
5